GHRP-6 vs Hexarelin

Side-by-side comparison of GHRP-6, Hexarelin — mechanism, dosing, half-life, side effects, and research status.

← Pick different peptides
Attribute GHRP-6 Growth Hormone Releasing Peptide-6 Growth Hormone Hexarelin Hexarelin (Examorelin) Growth Hormone
Basics
Molecular type Growth Hormone Releasing Peptide (GHRP)Growth Hormone Releasing Peptide (GHRP)
Amino acids 66
Molecular weight 873.0 Da887.1 Da
Half-life ~15–60 min~2 hours
Route(s) Subcutaneous, Intramuscular, IntranasalSubcutaneous, Intramuscular, Intranasal
Mechanism & Research
Primary mechanism GHRP-6 activates ghrelin receptors (GHSR-1a) in both the hypothalamus and pituitary. Hypothalamic activation reduces somatostatin release (enabling larger GH pulses) and strongly activates appetite pathways — explaining … Hexarelin activates GHSR-1a with exceptionally high potency, producing GH pulse amplitudes that exceed GHRP-2 and GHRP-6 at equivalent doses. It also acts at the hypothalamic level to suppress somatostatin, contributing …
Research status Research Compound Research Compound
Evidence summary GHRP-6 was one of the earliest compounds to enter GHRP clinical research, with human trials dating to the early 1990s. It has been used as a reference compound for characterising GHRP biology and ghrelin receptor pharmac… Hexarelin has Phase 1/2 clinical data including cardiac research. Its direct cardioprotective mechanism is one of the most distinctive features of any GHRP. Research also supports its use in GH deficiency testing.
Protocol & Dosing
Typical dose 100–300 mcg per injection100–200 mcg per injection
Frequency 2–3× daily2× daily
Duration 8–12 weeks4–6 weeks maximum (desensitisation concern)
Timing Fasted state or 2+ hours post-mealFasted state
Safety
Common side effects
  • Significant appetite increase (most common)
  • Cortisol elevation (dose-dependent)
  • Prolactin increase (transient)
  • Water retention
  • Cortisol elevation (significant at higher doses)
  • Prolactin increase
  • Rapid receptor desensitisation
  • Water retention
Contraindications
  • Active malignancy
  • Eating disorders (appetite amplification concern)
  • Hypothyroidism
  • Active malignancy
  • Cardiac conditions (paradoxical concern despite cardiac data — consult cardiologist)
  • Pregnancy
Anti-doping Prohibited (WADA S2) Prohibited (WADA S2)
Deeper reading
Related peptides Ipamorelin, GHRP-2, Hexarelin, CJC-1295 GHRP-2, GHRP-6, Ipamorelin
Full profile Read full GHRP-6 profile → Read full Hexarelin profile →

Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.